148 related articles for article (PubMed ID: 16311351)
1. Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation.
Shien T; Tashiro T; Omatsu M; Masuda T; Furuta K; Sato N; Akashi-Tanaka S; Uehara M; Iwamoto E; Kinoshita T; Fukutomi T; Tsuda H; Hasegawa T
J Clin Pathol; 2005 Dec; 58(12):1299-304. PubMed ID: 16311351
[TBL] [Abstract][Full Text] [Related]
2. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
3. Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation.
Tsuda H; Morita D; Kimura M; Shinto E; Ohtsuka Y; Matsubara O; Inazawa J; Tamaki K; Mochizuki H; Tamai S; Hiraide H
Cancer Sci; 2005 Jan; 96(1):48-53. PubMed ID: 15649255
[TBL] [Abstract][Full Text] [Related]
4. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
[TBL] [Abstract][Full Text] [Related]
5. Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated-type breast carcinomas with 'stem-cell-like' features.
Tsuda H; Tani Y; Weisenberger J; Kitada S; Hasegawa T; Murata T; Tamai S; Hirohashi S; Matsubara O; Natori T
Cancer Sci; 2005 Jun; 96(6):333-9. PubMed ID: 15958055
[TBL] [Abstract][Full Text] [Related]
6. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
7. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
8. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.
Shackney SE; Pollice AA; Smith CA; Janocko LE; Sweeney L; Brown KA; Singh SG; Gu L; Yakulis R; Lucke JF
Clin Cancer Res; 1998 Apr; 4(4):913-28. PubMed ID: 9563885
[TBL] [Abstract][Full Text] [Related]
9. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
10. Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast.
Park SS; Kim JE; Kim YA; Kim YC; Kim SW
Histopathology; 2005 Dec; 47(6):625-30. PubMed ID: 16324201
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor gene amplification and protein overexpression in basal-like carcinoma of the breast.
Shao MM; Zhang F; Meng G; Wang XX; Xu H; Yu XW; Chen LY; Tse GM
Histopathology; 2011 Aug; 59(2):264-73. PubMed ID: 21884205
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
[TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ
Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782
[TBL] [Abstract][Full Text] [Related]
14. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
15. The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/multicentric invasive ductal carcinoma of breast.
Choi Y; Kim EJ; Seol H; Lee HE; Jang MJ; Kim SM; Kim JH; Kim SW; Choe G; Park SY
Hum Pathol; 2012 Jan; 43(1):48-55. PubMed ID: 21733550
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of EGFR, p185(erbB-2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women.
Talley L; Chhieng DC; Bell WC; Grizzle WE; Frost AR
Biotech Histochem; 2008 Feb; 83(1):5-14. PubMed ID: 18568671
[TBL] [Abstract][Full Text] [Related]
17. Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast.
Lee Y; Cho S; Seo JH; Shin BK; Kim HK; Kim I; Kim A
Am J Clin Pathol; 2007 Dec; 128(6):1041-9. PubMed ID: 18024331
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study.
Ma BB; Poon TC; To KF; Zee B; Mo FK; Chan CM; Ho S; Teo PM; Johnson PJ; Chan AT
Head Neck; 2003 Oct; 25(10):864-72. PubMed ID: 12966511
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis of expression of a 65 kDa oncofetal protein (p65), epidermal growth factor receptor (EGFR), oncogene c-erb B2 and tumor suppressor gene p53 protein products in breast cancer patients.
Niewiadomska H; Mirowski M; Stempień M; Błoński JZ; Czyz W; Switalska J; Matyga E; Hanausek M; Wierzbicki R
Neoplasma; 2000; 47(1):8-14. PubMed ID: 10870681
[TBL] [Abstract][Full Text] [Related]
20. Breast carcinoma with chondroid differentiation: a clinicopathologic study of 21 triple negative (ER-, PR-, Her2/neu-) cases.
Gwin K; Wheeler DT; Bossuyt V; Tavassoli FA
Int J Surg Pathol; 2010 Feb; 18(1):27-35. PubMed ID: 19282292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
